Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma

BACKGROUND: To explore the efficacy and safety of crizotinib versus platinum‐based double agent chemotherapy as the first‐line treatment in patients with advanced anaplastic lymphoma kinase (ALK)‐positive lung adenocarcinoma. METHOD: We retrospectively analyzed data from 19 patients with advanced AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Quan, Qin, Na, Wang, Jinghui, Lv, Jialin, Yang, Xinjie, Li, Xi, Nong, Jingying, Zhang, Hui, Zhang, Xinyong, Wu, Yuhua, Zhang, Shucai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718131/
https://www.ncbi.nlm.nih.gov/pubmed/26816533
http://dx.doi.org/10.1111/1759-7714.12264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718131/
https://www.ncbi.nlm.nih.gov/pubmed/26816533
http://dx.doi.org/10.1111/1759-7714.12264

Ejemplares similares